Ulrika Wählby Hamrén

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

Eric A. F. Simões, Shabir A. Madhi, William J. Muller et al. · The Lancet Child & Adolescent Health · 2023 · 318 citations · Full text

Medicine, Infectious Diseases, Pediatrics +15

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Deidre Wilkins, Yuan Yuan, Yue Chang et al. · Nature Medicine · 2023 · 122 citations · Full text

Life Sciences, Immunology, Pediatrics +11

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk et al. · Nature Communications · 2023 · 76 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +11

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B. Domachowske, Yue Chang, Victoria Atanasova et al. · Journal of the Pediatric Infectious Diseases Society · 2023 · 33 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +10

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Deidre Wilkins, Ulrika Wählby Hamrén, Yue Chang et al. · PEDIATRICS · 2024 · 31 citations · Full text

Pharmacy, Immunology, Pediatrics +15